분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-11-06 23:08:16 , Hit : 2193
 Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients


Oct. 31, 2013 — New drug therapies offer promise to some hepatitis C sufferers whose transplanted livers are threatened by a recurrence of the disease, including some patients who have had no treatment options.


--------------------------------------------------------------------------------

Share This:
The encouraging findings are contained in two new studies by a collaboration of researchers across the U.S. -- as well as in Spain and New Zealand -- including Dilip Moonka, M.D., medical director of Liver Transplant at Henry Ford Hospital.

Both studies are being presented at the annual meeting of the American Association for the Study of Liver Diseases being held in Washington, DC, Nov. 1-5.

Both studies focused on the experimental anti-viral drug sofosbuvir, a direct-acting oral medication that may take the place of injectable interferon, which causes severe side effects in some patients.

The U.S. Food and Drug Administration is expected to decide in early December whether to approve its use for treating hepatitis C. Last week, the Antiviral Drugs Advisory Committee of the FDA voted unanimously in support of approval for sofosbuvir-based therapies for the treatment of chronic hepatitis C.

Chronic hepatitis C, which afflicts an estimated 3 million people in the U.S. alone, is a blood-borne viral disease that leads to scarring and deterioration of the liver. It is particularly insidious because patients usually don't develop symptoms until the scarring -- or cirrhosis -- is well underway.

Sofosbuvir, which belongs to a class of drugs known as nucleotide analogue polymerase inhibitors, acts at the molecular level by interfering with the RNA of the hepatitis C virus.

In the first newly released study, researchers tested it as an alternative to interferon, a naturally occurring protein that plays a role in fighting viral infections, but commonly produces a range of serious side effects.

The researchers used it in combination with ribavirin, which also inhibits the hepatitis C virus by interfering with its RNA to stem the replication of the virus and slow the progression of the disease. They sought to test the drug combination's effectiveness in preventing recurrence of hepatitis C in liver transplant recipients.

A total of 61 chronic hepatitis C patients with liver cancer were enrolled in the study and given both sofosbuvir and ribavirin daily for up to 48 weeks before liver transplant. All of the patients had well-compensated cirrhosis, meaning their bodies were still functioning without too much trouble despite liver scarring. The researchers found that the new drug combination was both safe and effective in such patients and prevented post-transplant recurrence of the hepatitis C virus in more than 60 percent of them.

In the second newly released study, researchers focused on liver transplant recipients whose severe hepatitis C recurred after surgery and who either couldn't tolerate or didn't respond to approved antiviral therapies -- leaving them with no other effective treatment options. In such cases, experimental drugs can sometimes be tested under "compassionate use" protocols.

The researchers reported that as of April, 115 patients were approved for compassionate use of sofosbuvir combined with ribavirin and/or the anti-viral drug peginterferon. At the time of their report, 63 had started treatment.

After several weeks of treatment and study, the researchers concluded that patients with severe recurrence of hepatitis C after receiving transplanted livers were able to tolerate the drug regimen, which produced strong anti-viral effects. They reported "notable clinical improvements and/or disease stabilization in a majority of the patients."


Henry Ford Health System (2013, October 31). Experimental hepatitis C drug shows promise for preventing recurrence in liver transplant patients. ScienceDaily. Retrieved November 6, 2013, from http://www.sciencedaily.com­ /releases/2013/10/131031124620.htm







1107   Dynamic view of the MS genome  이성욱 2010/05/01 2764
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2593
1105   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 951
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2295
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3211
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1345
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2385
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 943
1099   Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2497
1098   Engineering Better Immune Cells  이성욱 2010/05/06 2747
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1279
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2730
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 1836
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 838
  Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2193
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2622
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 1834
1090   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1229
1089   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 678
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 754

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN